Entering text into the input field will update the search result below

Cara Therapeutics launches early-stage study of Korsuva in liver disease; shares up 2%

Feb. 28, 2018 10:50 AM ETCara Therapeutics, Inc. (CARA) StockBy: Douglas W. House, SA News Editor
  • Dosing is underway in a Phase 1 study evaluating the safety and pharmacokinetics of Cara Therapeutics' (NASDAQ:CARA +2.3%) Oral KORSUVA (difelikefalin) in patients with chronic liver disease (CLD). The open-label trial will enroll up to 60 subjects with CLD and up to 12 healthy patients for control.
  • Results will inform the design of a Phase 2 clinical trial in patients with moderate-to-severe CLD-associated pruritis.
  • KORSUVA is a peripherally acting kappa opioid receptor agonist that is also being developed for the treatment of acute and chronic pain. Its value proposition is opioid-like analgesia without the respiratory depression or intestinal tract inhibition (constipation).
  • Previously: Cara Therapeutics launches late-stage study of CR845 in CKD-aP (Jan. 31)

Recommended For You

More Trending News

About CARA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CARA--
Cara Therapeutics, Inc.